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Summary
The symposium discussed the pathobiology, classification, and
treatment of cutaneous lymphomas. Drs. Burg and Kadin
commented on the pathophysiology of mycosis fungoides/
Sezary syndrome and cutaneous CD30+ lymphoproliferative
disorders, respectively. A proposed classification of primary
cutaneous lymphomas from the EORTC was presented by Drs.
Kerl and Sterry. Dr. Jaffe presented a classification of cutaneous
lymphomas based on the REAL classification. All speakers
agreed that primary cutaneous lymphomas are usually dis-
tinctive in their clinical behavior and biology, and differ from
their nodal counterparts. The symposium concluded with re-
marks from Drs. Vonderheid and Hoppe on the therapeutic
approach to primary cutaneous lymphoid malignancies.
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A symposium chaired by Prof. Gunter Burg and Dr.
Elaine S. Jaffe focused on the pathophysiology, classifica-
tion, and treatment of cutaneous lymphomas. Primary
lymphomas of the skin differ in many ways from their
nodal counterparts, and these malignancies require spe-
cial consideration from the specialist. The program began
with a review of the pathogenesis of cutaneous T-cell
lymphoma (CTCL) or mycosis fungoides/Sezary syn-
drome (MF/SS) by Gunter Burg. He noted that the
pathologic and clinical manifestations of CTCL follow
from complex interactions between the neoplastic T cells
and the cells of the cutaneous microenvironment, mainly
keratinocytes and dendritic cells. An important factor
may be a switch from TH (T helper) 1 cells to TH 2 cells
during tumor development. The cytokines elaborated by
the neoplastic cells and bystander cells play a role both in
tumor development and the ensuing clinical manifesta-
tions. CTCL, like most other malignancies, goes through
stages of tumor evolution. Tumor progression may be
explained by stepwise accumulation of mutations involv-
ing DNA repair- and tumor-suppressor genes. The risk
for the accumulation of gene mutations increases with the
number of cell divisions, which normally is limited by cell
death owing to apoptosis or senescence of the cell. These
events depend on bcl-2 expression and telomerase activ-
ity, both of which are increased in CTCL and, therefore,
may be important factors in promoting unlimited cell
proliferation, driven by persistent antigenic stimulation.
CD30+ lymphoproliferative disorders (LPDs) of the
skin include lymphomatoid papulosis (LyP) and primary
cutaneous anaplastic large-cell lymphoma (ALCL). These
disorders, which were reviewed by Marshall Kadin, ex-
hibit a spectrum in both their pathologic features and
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clinical behavior. Multiple cytokines (TNF-a and TGF-(3)
produced by the T-cell clone appear to influence the
histologic features and clinical regression of the cutane-
ous lesions. CD30+ cutaneous LPDs appear distinct from
classical ALCL, and lack the t(2;5)(p23;q35) of the latter
malignancy. The most common cytogenetic abnormal-
ities involve chromosomal breakpoints at Ip36 and
10q24-26. Although the disease typically remains con-
fined to the skin for many years, extracutaneous disease
is seen in 25% of patients and is associated with a more
aggressive clinical course.
The symposium proceeded to a discussion of the
classification of primary cutaneous lymphomas. The
EORTC, noting that cutaneous lymphomas differ from
nodal lymphomas in clinical behavior and functional
markers, has proposed a classification for these diseases
(Table 1). Helmut Kerl presented an overview of cutane-
ous B-cell lymphomas and Wolfram Sterry presented the
EORTC perspective on T-cell malignancies. The tumors
are classified according to their usual clinical behavior,
indolent or aggressive. In addition, some entities have
been identified as provisional, and still others are under-
going continued discussion regarding their inclusion. The
EORTC group identifies a primary cutaneous lymphoma
as one presenting solely with cutaneous disease, without
detected extracutaneous spread for at least six months.
Elaine Jaffe presented a classification of cutaneous
lymphomas based on the principles of the revised Euro-
pean-American lymphoma (REAL) classification pro-
posed by the International Lymphoma Study Group
(ILSG). She noted that the premise of the REAL classi-
fication is the identification of disease entities, based on
pathologic, immunophenotypic, genetic and clinical fea-
tures. Therefore, if cutaneous involvement is a unique
aspect of a disease entity, this clinical fact is considered
integral to disease recognition. Indeed, there are a num-
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Table 1. EORTC classification of primary cutaneous tymphomas
Primary cutaneous T-cell
lymphomas
Primary cutaneous B-cell
lymphomas
Indolent
Mycosis fungoides
Sezary syndrome
Pagetoid reticulosis
Lymphomatoid papulosis
Large-cell CTCL, CD30+, includ-
ing anaplastic, immunoblastic,
pleomorphic
Aggressive
Large-cell CTCL, CD30- , includ-
ing immunoblastic pleomorphic
Provisional
Granulomatous slack skin disease
CTCL pleomorphic small/
medium sized
CD8+ CTCL
Indolent
Follicle center cell lymphoma of
head and trunk
Immunocytoma
Intermediate
Large B-cell lymphoma of the leg
Provisional
Intravascular CBL
Marginal-zone B-cell lymphoma
Plasmacytoma
For discussion: angiocentricity, gamma/delta CTCL, marginal-zone
B-cell lymphoma, and subcutaneous lymphoma.
Abbreviations: CTCL - cutaneous T-cell lymphoma; CBL - cutaneous
Bcell.
ber of T-cell malignancies for which cutaneous involve-
ment is essential (Table 2). B-cell lymphomas restricted to
the skin are rare, with the possible exception of cutaneous
follicle-center lymphoma. It differs from its morphologi-
cally similar nodal counterpart clinically, immunopheno-
typically, and at the genetic level (bcl-2 rearrangement-
negative). So-called cutaneous immunocytoma is felt to
be an extranodal marginal-zone lymphoma of MALT-
type. Cutaneous large B-cell lymphoma is usually asso-
ciated with a good prognosis, but it is not clear whether
this clinical behavior is related to low stage or to an
intrinsically different biology.
Dr. Jaffe concluded that the principles of the REAL
classification are applicable to cutaneous lymphomas,
and that organ-specific classification schemes are not
required. Indeed, such schemes may impede the recogni-
tion of features common to diseases involving multiple
anatomic sites; e.g., MALT-type lymphomas. Neverthe-
less, primary cutaneous lymphomas are frequently dis-
tinctive in their clinical behavior and biology.
The symposium concluded with an overview of the
treatment of primary cutaneous lymphomas from the
dermatologist's perspective by Eric Vonderheid, and from
the oncologist's perspective by Richard T. Hoppe. Dr.
Vonderheid reaffirmed the principles presented by Dr.
Burg, that MF/SS represent a continuum with respect
to tumor aggressiveness and risk for transformation. Both
parapsoriasis en plaques and patch-stage MF are con-
sidered part of this continuum, with plaque- and tumor-
stage MF representing the opposite extreme. In patients
with limited cutaneous disease, skin-directed chemother-
apy and/or radiotherapy may be curative in 30%-50% of
patients. Such approaches are also useful in palliating
Table 2. Classification of cutaneous lymphomas based on the REAL
classification.
Cutaneous T-cell lymphomas
Mycosis fungoides/ Sezary syndrome
Pagetoid reticulosis (oc/p and y/6)
Granulomatous slack skin disease
Follicular mucinosis
CD30+ cutaneous lymphoproliferative disease
Lymphomatoid papulosis
Cutaneous anaplastic large cell lymphoma
Subcutaneous panniculitis-like T-cell lymphoma
Other T-cell lymphomas with cutaneous involvement (nearly all)
T-PLL/T-CLL
Aggressive NK-cell leukemias
NK/T-cell 'angiocentric' lymphomas
Angioimmunoblastic T-cell lymphoma
Peripheral T-cell lymphoma, NOS
Adult T-cell leukemia/h/mphoma
Classical anaplastic large-cell lymphoma
Cutaneous B-cell lymphomas
Cutaneous follicle-center lymphoma
(Usually bcl-2 rearrangement/expression—negative)
Cutaneous marginal-zone B-cell lymphoma (cutaneous MALT-type
lymphoma)
So-called 'cutaneous immunocytoma'
Large B-cell lymphoma
Intravascular large B-cell lymphoma
Precursor B-lymphoblastic lymphoma
Abbreviations: T-PLL/T-CLL - T-cell prolymphocytic leukemia/T-cell
chronic h/mphocytic leukemia; NK - natural killer; NOS - not other-
wise specified; MALT - mucosal-associated lymphoid tissue.
patients with more advanced disease. Biological response
modifiers and cytotoxics or immunotoxins targeted
against T cells hold promise for the future.
Dr. Hoppe confirmed the effectiveness of topical
therapies in control of disease. Because systemic disease
at presentation is rare, only limited staging is required
(chest radiographs, hematological evaluation with Sezary
cell counts, and routine chemistries). If significant lym-
phadenopathy is present, lymph node biopsy may be
indicated. Electron beam and topical nitrogen mustards
are both effective. Visceral disease requires systemic che-
motherapy, but chemotherapy generally has not been
effective. Interferon has shown some promise, and other
investigational approaches are indicated in patients with
advanced disease. Primary localized cutaneous B-ceLl
lymphoma is often treated successfully with localized
radiation therapy.
In conclusion, all speakers agreed that primary cuta-
neous lymphomas differ significantly from nodal and most
extranodal lymphomas, and that these malignancies re-
quire specialized diagnostic and therapeutic approaches.
The site of presentation must be taken into consideration
by both the pathologist and the clinician.
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